Description
Summary Information: Lortinib is a medication provided in the form of oral tablets, containing the active substance Erlotinib. Each tablet typically contains 150 mg of Erlotinib. Lortinib is primarily used in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. Erlotinib belongs to a class of medications known as tyrosine kinase inhibitors (TKIs), which work by blocking the action of the epidermal growth factor receptor (EGFR), a protein involved in the growth and spread of cancer cells.
Product Composition: The active pharmaceutical ingredient in Lortinib tablets is Erlotinib. Erlotinib selectively inhibits the tyrosine kinase activity of the EGFR, thereby blocking the signaling pathways that promote cancer cell growth and survival. In addition to Erlotinib, Lortinib tablets may contain various excipients and coatings to ensure proper formulation and stability.
Manufacturer: Lortinib tablets are manufactured by RPG Life Sciences Ltd, a leading Indian pharmaceutical company known for producing high-quality generic medications and innovative pharmaceutical formulations. RPG Life Sciences Ltd is committed to ensuring product efficacy, safety, and compliance with regulatory standards.
Package: Lortinib tablets are typically supplied in packs containing ten tablets, each with a dosage strength of 150 mg of Erlotinib. The packaging may include information such as the expiration date, lot number, and manufacturer details.
Usage Instructions: Lortinib tablets are taken orally with water, usually once daily, or as directed by a healthcare professional. The dosage and duration of treatment may vary depending on factors such as the type and stage of cancer, EGFR mutation status, and individual patient response. It is essential to follow the prescribed regimen closely and not to exceed recommended dosages without medical supervision.
Benefits:
- Effective Cancer Treatment: Lortinib is effective in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer, particularly in patients with EGFR mutations.
- Targeted Therapy: Erlotinib specifically targets the EGFR, a protein that is overexpressed in many cancer types, thereby inhibiting cancer cell growth and proliferation.
- Improved Survival Rates: Lortinib treatment has been shown to improve overall survival rates and progression-free survival in patients with advanced or metastatic NSCLC and pancreatic cancer.
- Well-Tolerated: Lortinib is generally well-tolerated, with manageable side effects such as rash, diarrhea, and fatigue reported infrequently, allowing for improved treatment adherence and patient comfort.
It is important to note that Lortinib should only be used under the supervision of a qualified healthcare professional experienced in the management of cancer. Patients should be monitored regularly for treatment response and potential side effects, and appropriate supportive care should be provided as needed throughout the course of treatment.
Reviews
There are no reviews yet.